-
-
-
-
-
-
-
Harrow to acquire Tyrvaya nasal spray for dry eye in $100M deal
-
-
-
-
-
-
-
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
-
-
-
-
-
-
-
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
-
-
-
-
-
-
-
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
-
-
-
-
-
-
-
Harrow Launches Harrow Access for All (HAFA)
-
-
-
-
-
-
-
Harrow Health (HROW) Acquires U.S. Commercial Rights to BYQLOVI
-
-
-
-
-
-
-
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
-
1,199,254 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


